FIRST AMENDMENT TO THE AMENDED AND RESTATED COLLABORATION LICENSE AGREEMENT BETWEEN OSI PHARMACEUTICALS, INC. AND AVEO PHARMACEUTICALS, INC.Collaboration License Agreement • August 6th, 2010 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment (the “Amendment”) effective as of the last date set forth on the signature page hereof, by and between OSI Pharmaceuticals, Inc. (“OSI”) and AVEO Pharmaceuticals, Inc. (“AVEO”) amends the Amended and Restated Collaboration License Agreement between OSI and AVEO, dated July 16, 2009 (the “Agreement”).
COLLABORATION & LICENSE AGREEMENTCollaboration & License Agreement • April 16th, 2020 • Immatics B.V. • Texas
This COLLABORATION & LICENSE AGREEMENT (this “Agreement”) is entered into as of August 17, 2015 (the “Effective Date”) by and between IMMATICS US INC., a corporation organized and existing under the laws of Delaware (“Immatics US”) and The University of Texas M. D. Anderson Cancer Center, (“MD Anderson”), a member institution of The University of Texas System (“System”), with a place of business at 1515 Holcombe Blvd., Houston, Texas. Immatics US and MD Anderson are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED UNIVERSITY OF PENNSYLVANIA...Collaboration & License Agreement • March 27th, 2023 • BioNTech SE • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Collaboration & License Agreement (“Amendment”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd, 9th Floor, Philadelphia, PA 19104-4310, and BioNTech SE, a German corporation (“Sponsor”), having a place of business at An der Goldgrube 12, 55131 Mainz, Germany is effective September 8, 2021 (“Amendment Effective Date”). Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH COLLABORATION LICENSE AGREEMENT BY AND BETWEEN EMISPHERE TECHNOLOGIES, INC. AND NOVARTIS PHARMA AGCollaboration License Agreement • March 30th, 2005 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
This Research Collaboration License Agreement (the “Agreement”), dated and effective as of September __, 2004 (the “Effective Date”) is between Emisphere Technologies, Inc., a Delaware corporation with offices at 765 Old Saw Mill River Road, Tarrytown, New York 10591, USA (“Emisphere”), and Novartis Pharma AG, a company registered in Switzerland with offices at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”) and Novartis and Emisphere shall each be a “Party” and together the “Parties”.
